HUTCHMED (China) Limited

Dr. Merrick Kanye, our Managed Director and Chief Medical Officer of HutchMed International, Dr. Karen Atkin, our Chief Operating Officer, and Mr. Hong Chen, our Chief Commercial Officer of China. So with that, I will hand over to Dr. Su.

Thanks, Mark.

Hello, everyone. As you all know, the biotech industry is going through some significant changes. HutchMED is trying to stay focused on our goals and objectives. During the first half of 2022, HutchMED China Commercial continued to grow and deliver strong results, particularly fulfilling considering the impact from the COVID disruptions. Ellunate continues to gain in prescription share for third-line CRC. The lead over Stavaga continued to widen. Celenda was included into the NRDL this year with a 52% price reduction, yet sales grew 69% aided by much improved patient access. All pathos also deliver strong sequential growth compared to second half 2021. On the pipeline, while we were disappointed by this zero fat in the US FDA CRL and now MAA withdrawal, our deep and broad pipeline continues to progress. Our first multinational MRCT for frequentinib global registration will read out shortly in August. And if positive, NDA filings will begin towards end of the year, starting from the US, followed by EU and Japan. For savalitinib, multiple registration studies, including global MRCT SAMETA for PRCC and CEFRON, for non-small cell lung cancer are enrolling. The SAVANNAH study, data to be disclosed at WCLC shortly, is also continuing to enroll with potential for filing for accelerated approval. Registration studies for our second wave of products, Emdesilicib, Solve the Planet, and Tesmetastat are all enrolling. and NDA submissions in China are expected during 23 and 24. Finally, managing changes and challenges. HutchMED has gone through many difficult stretches in our history. The management team is very experienced in dealing with challenges such as our zero fattening setback or the COVID disruption in China or the overall and many more. Next, I'll ask Mr. Hong Chen, Chief Commercial Officer of China, to give an update on first half China oncology commercial performance. Chen Hong.